Overexpression of aldo-keto reductase 1C2 is associated with disease progression in patients with prostatic cancer

Histopathology

Volumn 57, Issue 3, 2010, Pages 384-394

  Huang, Kuo Hsuan ^a,b   Chiou, Shiow Her ^c   Chow, Kuan Chih ^c   Lin, Tze Yi ^d   Chang, Hui Wen ^d   Chiang, I Ping ^d   Lee, Meng Chih ^a  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^c NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

aldo keto reductase family 1 member C2; disease progression; drug resistance; prostatic cancer

Indexed keywords

ALDO KETO REDUCTASE 1 C2; ANDROGEN RECEPTOR; CISPLATIN; DOXORUBICIN; FLUOROURACIL; LYCOPENE; METHOTREXATE; OXIDOREDUCTASE; PROSTAGLANDIN F2 ALPHA; UNCLASSIFIED DRUG; VINBLASTINE;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CAUCASIAN; CELL PROTECTION; CHINESE; CONTROLLED STUDY; DRUG CYTOTOXICITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; SEQUENCE ANALYSIS; TISSUE MICROARRAY; TWO DIMENSIONAL GEL ELECTROPHORESIS;

AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXYSTEROID DEHYDROGENASES; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR CELLS, CULTURED;

EID: 77956634018     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03647.x     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J. Clin. 2007 57 43 66.
2. Annual reports of the Department of Health, the Executive Yuan, Republic of China, 2006.
3. Simoneau AR. Treatment- and disease-related complications of prostate cancer. Rev. Urol. 2006 8 S56 S67.
4. Hsu NY, Ho HC, Chow KC et al. Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer. Cancer Res. 2001 61 2727 2731.
5. Shen H, Kauvar L, Tew KD. Importance of glutathione and associated enzymes in drug response. Oncol. Res. 1997 9 295 302.
6. Ax W, Soldan M, Koch L, Maser E. Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. Biochem. Pharmacol. 2000 59 293 300.
7. Deng HB, Parekh HK, Chow KC, Simpkins H. Increased expression of dihydrodiol dehydrogenase induces resistance to cisplatin in human ovarian carcinoma cells. J. Biol. Chem. 2002 277 15035 15043.
8. Wang LS, Chow KC, Wu YC, Hsu NY, Lin TY. Inverse expressions of dihydrodiol dehydrogenase and glutathione-S-transferase in patients with esophageal squamous cell carcinoma. Int. J. Cancer 2004 111 246 251.
9. Ueda M, Hung YC, Chen JT et al. Infection of human papillomavirus and overexpression of dihydrodiol dehydrogenase in uterine cervical cancer. Gynecol. Oncol. 2006 102 173 181.
10. Tai HL, Lin TS, Chiou SH et al. Overexpression of aldo-keto reductase 1C2 as a high-risk factor in bladder cancer. Oncol. Rep. 2007 17 305 311.
11. Penning TM, Burczynski ME, Jez JM et al. Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem. J. 2000 351 67 77.
12. Wang S, Yang Q, Fung KM, Lin HK. AKR1C2 and AKR1C3 mediated prostaglandin D2 metabolism augments the PI3K/Akt proliferative signaling pathway in human prostate cancer cells. Mol. Cell. Endocrinol. 2008 289 60 66.
13. Greene FL, Page DL, Fleaming ID et al. American Joint Committee on Cancer, Manual for staging cancer, 6th edn. New York, NY: Springer, 2002.
14. Remmele W, Schicketanz KH. Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Pathol. Res. Pract. 1993 189 862 866.
15. Coughlin SS, Neaton JD, Sengupta A. Cigarette smoking as a predictor of death from prostate cancer in 348,874 men screened for the Multiple Risk Factor Intervention Trial. Am. J. Epidemiol. 1996 143 1002 1106.
16. Roberts WW, Platz EA, Walsh PC. Association of cigarette smoking with extraprostatic prostate cancer in young men. J. Urol. 2003 169 512 516.
17. Plaskon LA, Penson DF, Vaughan TL, Stanford JL. Cigarette smoking and risk of prostate cancer in middle-aged men. Cancer Epidemiol. Biomarkers Prev. 2003 12 604 609.
18. Chiang YY. Hepatocyte growth factor induces hypoxia-related interleukin-8 expression in lung adenocarcinoma cells. Mol. Carcinog. 2009 48 662 670.
19. Lou H, Du S, Ji Q, Stolz A. Induction of AKR1C2 by phase II inducers: identification of a distal consensus antioxidant response element regulated by NRF2. Mol. Pharmacol. 2006 69 1662 1672.
20. Riner TL, Lin HK, Peehl DM, Steckelbroeck S, Bauman DR, Penning TM. Human type 3 3alpha-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells. Endocrinology 2003 144 2922 2932.
21. Chow KC, Chiou SH, Ho SP et al. The elevated serum interleukin-6 correlates with the increased serum butyrate level in patients with nasopharyngeal carcinoma. Oncol. Rep. 2003 10 813 819.
22. Kim J, Park H, Im JY, Choi WS, Kim HS. Sodium butyrate regulates androgen receptor expression and cell cycle arrest in human prostate cancer cells. Anticancer Res. 2007 27 3285 3292.
23. Sreekumar A, Poisson LM, Rajendiran TM et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009 457 910 914.
24. Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY, Simons JW. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 1995 45 542 549.
25. Burczynski ME, Lin HK, Penning TM. Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 59 607 614.
26. Wang HW, Lin CP, Chiu JH et al. Reversal of inflammation-associated dihydrodiol dehydrogenases (AKR1C1 and AKR1C2) overexpression and drug resistance in nonsmall cell lung cancer cells by wogonin and chrysin. Int. J. Cancer 2007 120 2019 2027.
27. De Marzo AM, Platz EA, Sutcliffe S et al. Inflammation in prostate carcinogenesis. Nat. Rev. Cancer 2007 7 256 269.
28. Lin TS, Huang HH, Fan YH, Chiou SH, Chow KC. Genetic polymorphism and gene expression of microsomal epoxide hydrolase in non-small cell lung cancer. Oncol. Rep. 2007 17 565 572.
29. Chen JT, Lin TS, Chow KC et al. Cigarette smoking induces overexpression of hepatocyte growth factor in type II pneumocytes and lung cancer cells. Am. J. Respir. Cell Mol. Biol. 2006 34 264 273.
30. Lin TS, Chiou SH, Wang LS et al. Expression spectra of matrix metalloproteinases in metastatic non-small cell lung cancer. Oncol. Rep. 2004 12 717 723.